Assumption that the impact of COVID-19 will normalize in the fiscal year ending March 2022
First written in FY2021-Q1. 5 of 8 entries say "Restated". Latest entry: FY2023-Q1.
39 other companies' latest entry also says "Restated".
- FY2023-Q1RestatedAnnual report
「Regarding the future spread and timing of containment of COVID-19, there have been no material changes to the assumptions stated in the previous fiscal year's securities report under (Significant Accounting Estimates).」
It reconfirms that there have been no material changes from the previous fiscal year to the accounting assumptions concerning the spread and timing of containment of COVID-19. - FY2022SoftenedAnnual report
「Although the spread of COVID-19 is continuing, we expect its future impact on the pharmaceutical market to be limited.」
While maintaining the previous assumption that conditions will return to normal in the fiscal year ending March 2023, it indicates that the future impact on the pharmaceutical market is expected to be limited. - FY2022-Q2RestatedAnnual report
「Regarding the future spread and timing of containment of COVID-19, the Company assumes, without making any material changes to the assumptions stated in the previous fiscal year's securities report under (Significant Accounting Estimates), that the spread of infection will be contained during the current fiscal year and that conditions will return to normal in the fiscal year ending March 2023.」
It continues, without changing the accounting assumption, to assume that COVID-19 will be contained during the current fiscal year and that conditions will return to normal in the fiscal year ending March 2023. - FY2022-Q1RestatedAnnual report
「Regarding the future spread and timing of containment of COVID-19, the Company assumes that the spread of infection will be contained during the current fiscal year and that conditions will return to normal in the fiscal year ending March 2023.」
It continues to use the accounting assumption that COVID-19 will be contained during the current fiscal year and that conditions will return to normal in the fiscal year ending March 2023. It also notes the high uncertainty. - FY2021SoftenedAnnual report
「The impact of COVID-19 is expected to remain in the fiscal year ending March 2022, with pharmaceutical demand not recovering substantially and remaining at a level equivalent to that in the fiscal year ended March 2021. / Regarding the future spread and timing of containment of COVID-19, the Company assumes that the spread of infection will be contained during the fiscal year ending March 2022 and that conditions will return to normal in the fiscal year ending March 2023.」
The assumption has effectively been pushed back from a return to normal conditions in the fiscal year ending March 2022 to continued impact in that fiscal year and a return to normal conditions in the fiscal year ending March 2023. - FY2021-Q3RestatedAnnual report
「Regarding the future spread and timing of containment of COVID-19, the Company assumes that the spread of infection will be contained during the current fiscal year and that conditions will return to normal in the fiscal year ending March 2022.」
It continues to use the accounting assumption that conditions will return to normal in the fiscal year ending March 2022. However, it also notes the high uncertainty of the assumption. - FY2021-Q2RestatedAnnual report
「Regarding the future spread and timing of containment of COVID-19, the Company assumes that the spread of infection will be contained during the current fiscal year and that conditions will return to normal in the fiscal year ending March 2022.」
It continues to use the accounting assumption that conditions will return to normal in the fiscal year ending March 2022. It also notes the high uncertainty of the assumption. - FY2021-Q1First statedAnnual report
「Regarding the future spread and timing of containment of COVID-19, the Company assumes that the spread of infection will be contained during the current fiscal year and that conditions will return to normal in the fiscal year ending March 2022.」
For its accounting estimates, it assumes that the spread of infection will be contained during the current fiscal year and that conditions will return to normal in the fiscal year ending March 2022. It also states that, given the high uncertainty of this assumption, actual future results may differ if the situation is prolonged.